Has Firas Zahr, MD received payments from drug or device companies?

Yes. Drug and device makers reported $810,450 in general payments to Firas Zahr, MD across 1,333 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Firas Zahr, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Firas Zahr, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Firas Zahr, MD

Cardiovascular Disease · Portland, ORNPI 1568637049

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (42.3%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Edwards Lifesciences at 47.2% of the total. 2025 is the largest year on record at $286,926, more than ten times the $22,926 reported in 2019. Among cardiovascular disease clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$810,450in general payments, 2019–2025

Across 1,333 payments — averaging $607.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Edwards Lifesciences$382K
Medtronic$289K
Jenavalve Technology, Inc.$39K
Abiomed$22K
Biosense Webster, Inc.$21K
GE HealthCare$19K
plus $38K from 8 others

$6,994,211in research payments, 2019–2025

Across 342 payments — averaging $20,451 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Edwards Lifesciences$5.6M
Medtronic$797K
Philips North America LLC$481K
GE HealthCare$39K
Abbott$27K
Boston Scientific$396

What the payments were for

Consulting fees$342,63542%
Speaking & faculty fees$137,78917%
Grants$2,9300%
Travel & lodging$286,56335%
Food & beverage$40,5325%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Edwards Lifesciences	566	$382,469
Medtronic(2 entities)	629	$288,739
Jenavalve Technology, Inc.	12	$39,077
Abiomed	2	$22,100
Biosense Webster, Inc.	18	$21,225
GE HealthCare	10	$18,785
Abbott	35	$12,415
Siemens Medical Solutions USA, Inc.	25	$10,696
Philips North America LLC	14	$10,597
Ancora Heart, Inc.	5	$2,463
Boston Scientific	13	$1,473
Penumbra, Inc.	1	$235
Shockwave Medical, Inc	2	$145
Cathworks, Inc.	1	$29

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

PASCAL$78,819
COREVALVE EVOLUT R$60,138
Edwards SAPIEN 3 Transcatheter Heart Valve$44,801
JenaValve Pericardial TAVR System$38,879
APOLLOTM$33,087
EVOQUE$31,766
Impella$22,100
Carto 3$14,216
CoreValve Evolut$13,097
SYMPLICITY G3$10,500
(9520) IGT Devices Undivided$9,449
MitraClip$8,280
ACUSON SC2000 Diagnostic Ultrasound System$7,151
AccuCinch$2,463
VIVID$1,292
SAPIEN 3 Ultra RESILIA$1,176
(6554) Peripheral Vascular Undivided$1,063
Thermocool SF$1,015
ACUSON Origin Diagnostic Ultrasound System$555
3F$444

How this compares

$810,450 in reported general payments places this provider in the 95th percentile of 198 cardiovascular disease providers in Oregon.

See all cardiovascular disease providers in Oregon →

Medicare billing

Part B allowed, 2024

$122,460

Medicare patients

181

Services billed

403

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
ClopidogrelClopidogrel Bisulfate	34	$509

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Portland

Scott ChadderdonPortland$282K
Ahmad MasriPortland$227K
Stephen HeitnerPortland$105K
Abhushan PoudyalPortland$54K
Douglas DawleyPortland$45K
Kishor KhanalPortland$39K
Jeffrey MarbachPortland$19K
Laith AlkukhunPortland$16K
Tyler GluckmanPortland$15K
Sylvia Marie BisoPortland$14K

See the full list for Oregon →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →